Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
Open accessAbstract
The efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58%) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repeat IMiD (thalidomide [34; 24%] or lenalidomide [106; 76%]) as one of the salvage regimens. A median of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were administered before IMiD-based salvage therapy. The median time from diagnosis to repeat exposure to IMiD was 28 months. Among the 113 evaluable patients, 50 (44%) achieved at least a partial response, and 63 (56%) achieved less than a partial response to repeat IMiD. Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pomalidomide has demonstrated efficacy in around a third of patients with lenalidomide-refractory MM.
“The success of lenalidomide led to the development of pomalidomide, which has demonstrated efficacy in around a third of patients with lenalidomide-refractory MM42–44.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [44]
The citation lists haven’t been fetched yet
References 20 · Cited by 60
- Authors
- Madan, S., Lacy, M. Q., Dispenzieri, A., Gertz, M. A., Buadi, F., Hayman, S. R., Detweiler-Short, K., Dingli, D., Zeldenrust, S., Lust, J., Greipp, P. R., Rajkumar, S. V., & Kumar, S.
- Affiliations
- Mayo Clinic (US)
- Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-08-18
- Volume
- 118
- Issue
- 7
- Pages
- 1763-1765
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3158710
- OpenAlex
- W2053685717
- Cited by
- 60
- References
- 20
- Citations by year
- 2025: 1 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 6 · 2018: 2 · 2017: 3 · 2016: 7 · 2015: 10 · 2014: 5 · 2013: 5 · 2012: 6
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Foundation for Medical Education and Research
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, immunomodulators, retreatment, lenalidomide, thalidomide, dexamethasone, salvage therapy, first-line therapy, treatment response, stem cell transplantation
- MeSH terms
- Lenalidomide, Adult, Aged, Antineoplastic Agents, Dexamethasone, Female, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Thalidomide, Retreatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
